Schweizer MT - Search Results

1

PET-Based TheraP Eligibility and Outcomes of VISION-Eligible Patients with Metastatic Castration-Resistant Prostate Cancer Who Received ¹⁷⁷Lu-PSMA-617: Importance of ¹⁸F-FDG-Avid Discordant Findings.

Demirci RA, Ghodsi A, Gulati R, Behnia S, Nelson PS, Cheng HH, Yezefski TA, Haffner MC, Hawley JE, Montgomery RB, Yu EY, Schweizer MT, Chen DL, Iravani A. Demirci RA, et al. Among authors: schweizer mt. J Nucl Med. 2025 Jan 3;66(1):47-53. doi: 10.2967/jnumed.124.268167. J Nucl Med. 2025. PMID: 39542703

2

Genomic Correlates of Prostate-Specific Membrane Antigen Expression and Response to ¹⁷⁷Lu-PSMA-617: A Retrospective Multicenter Cohort Study.

Raychaudhuri R, Mo G, Tuchayi AM, Graham L, Gulati R, Pritchard CC, Haffner MC, Yezefski T, Hawley JE, Cheng HH, Yu EY, Grivas P, Montgomery RB, Nelson PS, Chen DL, Hope T, Iravani A, Schweizer MT. Raychaudhuri R, et al. Among authors: schweizer mt. JCO Precis Oncol. 2024 Apr;8:e2300634. doi: 10.1200/PO.23.00634. JCO Precis Oncol. 2024. PMID: 38662984

3

SPECT/CT in Early Response Assessment of Patients with Metastatic Castration-Resistant Prostate Cancer Receiving ¹⁷⁷Lu-PSMA-617.

Demirci RA, Gulati R, Hawley JE, Yezefski T, Haffner MC, Cheng HH, Montgomery RB, Schweizer MT, Yu EY, Nelson PS, Chen DL, Iravani A. Demirci RA, et al. Among authors: schweizer mt. J Nucl Med. 2024 Dec 3;65(12):1945-1951. doi: 10.2967/jnumed.124.267665. J Nucl Med. 2024. PMID: 39510589

4

Persistent androgen receptor addiction in castration-resistant prostate cancer.

Schweizer MT, Yu EY. Schweizer MT, et al. J Hematol Oncol. 2015 Nov 13;8:128. doi: 10.1186/s13045-015-0225-2. J Hematol Oncol. 2015. PMID: 26566796 Free PMC article. Review.

5

Schweizer MT, Gulati R, Mostaghel EA, Nelson PS, Montgomery RB, Yu EY, Cheng HH. Schweizer MT, et al. Med Oncol. 2016 Jul;33(7):77. doi: 10.1007/s12032-016-0793-1. Epub 2016 Jun 14. Med Oncol. 2016. PMID: 27300548 Free PMC article.

6

AR-Signaling in Human Malignancies: Prostate Cancer and Beyond.

Schweizer MT, Yu EY. Schweizer MT, et al. Cancers (Basel). 2017 Jan 11;9(1):7. doi: 10.3390/cancers9010007. Cancers (Basel). 2017. PMID: 28085048 Free PMC article. Review.

7

A phase I study of niclosamide in combination with enzalutamide in men with castration-resistant prostate cancer.

Schweizer MT, Haugk K, McKiernan JS, Gulati R, Cheng HH, Maes JL, Dumpit RF, Nelson PS, Montgomery B, McCune JS, Plymate SR, Yu EY. Schweizer MT, et al. PLoS One. 2018 Jun 1;13(6):e0198389. doi: 10.1371/journal.pone.0198389. eCollection 2018. PLoS One. 2018. PMID: 29856824 Free PMC article. Clinical Trial.

8

Clinical determinants for successful circulating tumor DNA analysis in prostate cancer.

Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, De Sarkar N, Yu EY, Montgomery RB, Nelson PS, Pritchard CC. Schweizer MT, et al. Prostate. 2019 May;79(7):701-708. doi: 10.1002/pros.23778. Epub 2019 Mar 13. Prostate. 2019. PMID: 30865311 Free PMC article.

9

"Matching" the "Mismatch" Repair-Deficient Prostate Cancer with Immunotherapy.

Schweizer MT, Yu EY. Schweizer MT, et al. Clin Cancer Res. 2020 Mar 1;26(5):981-983. doi: 10.1158/1078-0432.CCR-19-3780. Epub 2020 Jan 3. Clin Cancer Res. 2020. PMID: 31900277 Free PMC article.

10

Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies.

Graham LS, Montgomery B, Cheng HH, Yu EY, Nelson PS, Pritchard C, Erickson S, Alva A, Schweizer MT. Graham LS, et al. Among authors: schweizer mt. PLoS One. 2020 May 26;15(5):e0233260. doi: 10.1371/journal.pone.0233260. eCollection 2020. PLoS One. 2020. PMID: 32453797 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

116 results

Search Page

Filters